systemic scleroderma
Information
- Disease name
- systemic scleroderma
- Disease ID
- DOID:418
- Description
- "A scleroderma that is characterized by fibrosis (or hardening) of the skin and major organs, as well as vascular alterations, and autoantibodies." [url:https\://ghr.nlm.nih.gov/condition/systemic-scleroderma] {comment="sn:IEDB"}
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01413100 | Active, not recruiting | Phase 2 | Scleroderma Treatment With Autologous Transplant (STAT) Study | September 15, 2011 | August 2024 |
| NCT00278525 | Completed | Phase 2 | Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma | September 2005 | December 2012 |
| NCT00318175 | Completed | Phase 2 | Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis | June 2006 | May 2007 |
| NCT00318188 | Completed | N/A | Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis | September 2005 | January 2014 |
| NCT00522002 | Completed | CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study | August 2007 | June 2010 | |
| NCT00622895 | Completed | Phase 1/Phase 2 | Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis | September 1, 2006 | August 1, 2017 |
| NCT00004563 | Completed | Phase 3 | Scleroderma Lung Disease | August 1999 | May 2013 |
| NCT00697736 | Completed | N/A | Cardiac Repercussion of Systemic Sclerodermias | March 2007 | December 2014 |
| NCT01295736 | Completed | Phase 3 | Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY | November 2010 | August 2013 |
| NCT01309997 | Completed | Phase 2 | Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease | March 2011 | December 2015 |
| NCT02213705 | Completed | Phase 1/Phase 2 | Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells | May 6, 2014 | June 16, 2022 |
| NCT02349009 | Completed | Phase 1/Phase 2 | Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial | June 2015 | September 2016 |
| NCT03262922 | Completed | Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment | July 29, 2016 | February 18, 2022 | |
| NCT03575156 | Completed | N/A | Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis | September 20, 2018 | September 14, 2021 |
| NCT06056921 | Recruiting | Phase 1 | Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease | August 31, 2023 | August 31, 2026 |
| NCT04380831 | Recruiting | Early Phase 1 | TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis | February 24, 2022 | December 22, 2024 |
| NCT05672992 | Recruiting | N/A | Longitudinal Spatial Frequency Domain Imaging Study | February 10, 2023 | June 2026 |
| NCT05726630 | Recruiting | Phase 3 | Clinical Study of Divozilimab in Patients With Systemic Scleroderma | December 26, 2022 | February 1, 2025 |
| NCT03816345 | Recruiting | Phase 1 | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | July 16, 2019 | August 31, 2024 |
| NCT00377455 | Terminated | Phase 2 | Placebo Controlled Trial of Bosentan in Scleroderma Patients | September 2006 | March 2010 |
| NCT00628797 | Terminated | Phase 1/Phase 2 | Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis | February 2008 | November 2013 |
| NCT01410903 | Terminated | N/A | Immunoadsorption in Patients With Severe Systemic Sclerosis | April 2011 | August 2012 |
| NCT01559129 | Terminated | Phase 2 | Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease | August 9, 2012 | November 3, 2016 |
| NCT03816189 | Unknown status | Role of Eosinophil in Fibrogenesis of Systemic Sclerosis | October 3, 2018 | December 2021 | |
| NCT03508375 | Unknown status | N/A | Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis | May 15, 2018 | November 2021 |
| NCT03629002 | Unknown status | BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA | September 2018 | September 2020 | |
| NCT01047072 | Withdrawn | Phase 2 | Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis |
- Disase is a (Disease Ontology)
- DOID:419
- Cross Reference ID (Disease Ontology)
- EFO:0000717
- Cross Reference ID (Disease Ontology)
- GARD:9748
- Cross Reference ID (Disease Ontology)
- ICD10CM:M34.0
- Cross Reference ID (Disease Ontology)
- ICD9CM:710.1
- Cross Reference ID (Disease Ontology)
- MESH:D012595
- Cross Reference ID (Disease Ontology)
- MIM:181750
- Cross Reference ID (Disease Ontology)
- NCI:C72070
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:89155008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0036421
- Exact Synonym (Disease Ontology)
- progressive systemic sclerosis
- Exact Synonym (Disease Ontology)
- Scleroderma
- Exact Synonym (Disease Ontology)
- Scleroderma syndrome
- Exact Synonym (Disease Ontology)
- systemic sclerosis